Summary
Objective
Methods
Results
Conclusions
Keywords
Introduction
Materials and methods
Experimental design
Identification of differentially expressed genes (DEGs)

1. Metabolism 1.0 Global overview
2.1 Folding, sorting and degradation
3.1 Circadian rhythm (3) | 3.2 Signal transduction
4.1 Transport and catabolism
|
5. Organismal systems 5.1 Immune system
| 5.4 Digestive system
|
Validation of salient genes differentially expressed in microarray analysis
Functional annotation and molecular network analysis
Statistical analysis
Results
Temporal regulation of gene expression by exercise
DAVID GO-term functional annotation enrichment analysis

KEGG pathway analysis of molecular interaction and reaction networks
- (i)Metabolism. Exercise regulated pathways involved in intermediate metabolism, such as synthesis of carbohydrates, energy, lipids, nucleotides, amino acids, glycans, co-factors/vitamins, terpenoids/polyketides, and xenobiotics.
- (ii)Genetic information processing. While exercise upregulated pathways involved in DNA repair, translation, folding, sorting and degradation of proteins, it suppressed DNA replication pathways. For example, exercise suppressed several genes integrally associated with the cell cycle, such as S100a9 and cyclins, regulators of the cell cycle and mitosis. Furthermore, Igf1, Igfbp6 and Pdgfb, growth factors important in the regulation of cell division, were also suppressed28,29.
- (iii)Environmental information processing. Surprisingly, exercise upregulated Per2, Cry1 and Cry2 genes that regulate circadian rhythms30.
- (iv)Cellular processes. Exercise regulated pathways that control cellular transport and catabolism, including such activities as Fc-gamma mediated phagocytosis, endocytosis, and lysosome and peroxisome functions. Exercise also regulated cell motility, growth and death, and cell communication by regulating actin cytoskeleton, cell cycle, apoptosis, cell adherence and cell junctions.
- (v)Organismal systems. Surprisingly, exercise regulated many of the pathways involved in organismal functions in cartilage. For example, exercise controlled at least 20 pathways in immune (soluble and cellular immune responses), 11 in endocrine (renin-angiotensin, insulin, thyroid stimulating hormone, lipolysis, etc), eight in digestive (protein, fat, carbohydrate absorption, digestive secretions), eight in nervous (long term depression, several synapses), three in circulatory (smooth & cardiac muscle contraction) systems, two in sensory (inflammatory mediator regulation, olfactory transduction), development (osteoclastogenesis), and environmental adaptation (circadian entrainment) (Table II).
- (vi)Human disease. KEGG mapper also revealed that exercise regulated genes associated with diseases, likely due to involvement of signaling cascades, growth factors and metabolic pathways. We did not explore these genes in detail, but a list of these diseases and pathways is provided in Supplementary Table S2.

Examination of major exercise-driven pathways in cartilage
ECM biosynthesis and metabolism
Gene symbol | Day 0 | Day 2 | Day 5 | Day 15 | |
---|---|---|---|---|---|
ECM structural proteins (gene name) | |||||
Decorin | Dcn | 1 | 2.04 | 2.62 | 4.18 |
Fibroblast growth factor 2 | Fgf2 | 1 | 2.65 | 2.84 | 2.73 |
Integrin 5 | Itga5 | 1 | 1.76 | 1.97 | 2.09 |
Phospholipase C | Plce1 | 1 | 4.18 | 4.02 | 4.21 |
Protein kinase C, alpha | Prkca | 1 | 1.75 | 1.97 | 1.94 |
Syndecan | Sdc4 | 1 | 2.05 | 1.87 | 2.23 |
Chondroitin sulfate N-acetylgalactosaminyltransferase 2 | Csgalnact2 | 1 | 2.24 | 2.39 | 1.98 |
Chondroitin 6 | Chst3 | 1 | 2.38 | 2.47 | 2.50 |
Keratan sulfate Gal-6 sulfotransferase 1 | Chst1 | 1 | 2.44 | 3.52 | 2.67 |
ST6 Beta-galactosamide alpha-2,6-sialyltranferase 1 | St6gal1 | 1 | 2.85 | 2.81 | 2.29 |
Heparan sulfate 3-O-sulfotransferase 1 | Hs3st1 | 1 | 2.82 | 3.08 | 3.67 |
Versican | Vcan | 1 | 3.47 | 3.14 | 4.01 |
Carbohydrate (Keratan Sulfate Gal-6) Sulfotransferase 1 | Chst1 | 1 | 2.44 | 3.52 | 2.67 |
Carbohydrate (Keratan Sulfate Gal-6) Sulfotransferase 3 | Chst3 | 1 | 2.38 | 2.47 | 2.50 |
Heparan sulfate (glucosamine) 3-O-sulfotransferase 1 | Hs3st1 | 1 | 2.82 | 3.08 | 3.67 |
Cytokine-like 1 | Cytl1 | 1 | 4.52 | 5.06 | 5.71 |
Cartilage intermediate layer protein | Cilp_pred | 1 | 1.99 | 2.08 | 2.47 |
Cartilage intermediate layer protein 2 | Cilp2_pred | 1 | 1.76 | 1.90 | 2.35 |
CS N-acetylgalactosaminyltransferase-1 | Csgalnact2 | 1 | 2.24 | 2.40 | 1.97 |
Matrilin 4 | Matn4 | 1 | −2.90 | −3.11 | −2.82 |
Collagen, Type XXIV, Alpha 1 | Col24a1 | 1 | −2.12 | −2.02 | −2.32 |
Collagen, Type IX, Alpha 2 | Col9a2 | 1 | −2.16 | −2.35 | −2.23 |
Proteoglycan 2 | Prg2 | 1 | −4.56 | −3.87 | −4.30 |
Matrilin 3 | Matn3_pred | 1 | −5.95 | −8.91 | −12.28 |
Tenascin N | Tnn | 1 | −2.98 | −2.19 | −1.63 |
Collagen type I alpha 2 | Col1a2 | 1 | −2.03 | −2.00 | −1.41 |
Collagen, type IX alpha 3 | Col9a3_pred | 1 | −1.95 | −2.23 | −2.18 |
Periostin, osteoblast specific factor | Postn_pred | 1 | −4.11 | −3.70 | −1.97 |
Inhibitors of ECM degradation | |||||
Serpin peptidase inhibitor, Clade A (antitrypsin) | Serpina1 | 1 | 4.86 | 12.15 | 12.36 |
Serpin Peptidase Inhibitor, Clade A memb3 | Serpina3n | 1 | 4.79 | 4.37 | 5.05 |
Murinoglobulin 1 | Mug1 | 1 | 2.69 | 2.74 | 3.00 |
Murinoglobulin 2 | Mug2 | 1 | 2.57 | 3.28 | 3.01 |
Mannan-Binding Lectin Serine Peptidase 1 | Masp1 | 1 | 2.60 | 2.85 | 2.59 |
TIMP metallopeptidase inhibitor 4 | Timp4 | 1 | 1.51 | 1.46 | 1.71 |
Serpin peptidase inhibitor, clade A | Serpinb1a | 1 | −4.62 | −4.04 | −2.40 |
Alpha-2-macroglobulin | A2m | 1 | −2.17 | −2.13 | −2.47 |
Cathepsin K | Ctsk | 1 | −2.86 | −3.58 | −2.48 |
ADAM metallopeptidase thrombospondin type1 motif, 3 | Adamts3 | 1 | −3.00 | −4.36 | −4.98 |
Matrix metallopeptidase 8 (neutrophil collagenase) | Mmp8 | 1 | −2.42 | −3.17 | −2.37 |
Dipeptidyl-peptidase 4 | Dpp4 | 1 | −3.81 | −3.87 | −4.03 |
Matrix metallopeptidase 9 (gelatinase B) | Mmp9 | 1 | −8.20 | −11.32 | −7.84 |
ADAM metallopeptidase thrombospondin type1 motif, 14 | Adamts14_pred | 1 | −2.47 | −2.36 | −2.47 |
ADAM metallopeptidase thrombospondin type1 motif, 3 | Adamts3 | 1 | −2.48 | −3.90 | −3.31 |
Matrix Metallopeptidase 3 | Mmp3 | 1 | 2.06 | 2.13 | 1.53 |
Matrix Metallopeptidase 14 | Mmp14 | 1 | −1.92 | −2.50 | −2.02 |
Heparanase | Hpse | 1 | 1.27 | 1.05 | 2.01 |
Immune function
Gene name | Gene symbol | Day 0 | Day 2 | Day 5 | Day 15 |
---|---|---|---|---|---|
Chemokine (C-X-C motif) ligand 13 | Cxcl13 | 1 | 2.25 | 4.37 | 9.85 |
Interleukin 16 | Il16 | 1 | 2.62 | 3.07 | 2.69 |
Interleukin 1 receptor, type II | Il1r2 | 1 | 1.72 | 1.65 | 2.01 |
Interleukin 17B | Il17b | 1 | 1.83 | 2.24 | 2.02 |
Interleukin 1 receptor, type I | Il1r1 | 1 | 2.10 | 2.04 | 1.77 |
Interleukin 6 receptor | Il6ra | 1 | 2.18 | 2.61 | 1.92 |
Lipopolysaccharide binding protein | Lbp | 1 | 1.80 | 1.89 | 3.00 |
Thrombospondin 2 | Thbs2 | 1 | 3.77 | 3.99 | 3.95 |
Plasminogen activator, tissue | Plat | 1 | 2.06 | 2.37 | 4.25 |
FK506 binding protein 5 | Fkbp5 | 1 | 6.50 | 6.70 | 8.11 |
Clusterin | Clu | 1 | 2.71 | 2.71 | 3.20 |
Phosphodiesterase 10A | Pde10a | 1 | 2.58 | 2.34 | 2.61 |
Phosphodiesterase 3A | Pde3a | 1 | 2.04 | 2.14 | 2.16 |
Phospholipase D5 (inactive) | Pld5 | 1 | 11.19 | 12.71 | 8.19 |
Phospholipase C1 | Plce1 | 1 | 4.18 | 4.02 | 4.21 |
Phospholipase a1 | Pla1a | 1 | 2.25 | 2.70 | 3.14 |
Phosphodiesterase 3B | Pde3b | 1 | 2.62 | 2.28 | 1.74 |
6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 | Pfkfb3 | 1 | 2.29 | 1.76 | 1.56 |
Phospholipase A2, group IIA | Pla2g2a | 1 | 1.03 | 1.87 | 9.74 |
Cathepsin S | Ctss | 1 | 1.05 | 1.27 | 2.86 |
Heat shock 22 kDa protein 8 | Hspb8 | 1 | 3.47 | 3.51 | 3.73 |
Heat shock protein 90 kDa alpha (cytosolic), class A 1 | Hsp90aa1 | 1 | 2.09 | 2.10 | 2.11 |
Heat shock protein 105 | Hsph1 | 1 | 3.38 | 3.17 | 3.00 |
Heat shock 70 kDa protein 1B | Hspa1b | 1 | 1.54 | 1.99 | 3.43 |
Tumor necrosis factor receptor superfamily, member 11b | Tnfrsf11b | 1 | 1.84 | 1.83 | 2.27 |
Plasminogen activator, tissue | Plat | 1 | 2.06 | 2.37 | 4.25 |
Serpin peptidase inhibitor, clade A | Serpina1 | 1 | 4.86 | 12.15 | 12.36 |
Serpin peptidase inhibitor, clade A member 3N | Serpina3n | 1 | 4.79 | 4.37 | 5.05 |
Complement component 1, q subcomponent, C chain | C1qc | 1 | −1.34 | −1.10 | 2.14 |
Chemokine (C-X-C motif) receptor 4 | Cxcr4 | 1 | −3.30 | −3.10 | −2.65 |
Arachidonate 15-lipoxygenase | Alox15 | 1 | −2.32 | −2.06 | −2.81 |
Prostaglandin-endoperoxide synthase 2 | Ptgs2 | 1 | −2.24 | −2.57 | −2.15 |
Complement component 3 | C3 | 1 | −3.50 | −2.81 | −2.05 |
Complement component 7 | C7 | 1 | −2.66 | −3.69 | −2.12 |
Neutrophilic granule protein | Ngp | 1 | −7.07 | −6.77 | −3.86 |
Interferon regulatory factor 8 | Irf8 | 1 | −2.31 | −2.78 | −1.72 |
Defensin, alpha 1 | Defa | 1 | −7.36 | −6.30 | −1.81 |
CD93 molecule | C1qr1 | 1 | −2.24 | −2.65 | −1.35 |
Lysozyme | Lyz | 1 | −4.23 | −4.31 | 1.19 |
Chemokine (C-X-C motif) receptor 2 | Il8rb | 1 | −2.07 | −1.76 | −1.82 |
Chemokine (C–C motif) receptor 1 | Ccr1 | 1 | −2.29 | −3.04 | −1.79 |
Chemokine (C-X-C motif) ligand 12 | Cxcl12 | 1 | −2.35 | −2.97 | −1.82 |
Serpin Peptidase Inhibitor, Clade A | Serpinb1a | 1 | −4.62 | −4.04 | −2.40 |
Coagulation factor V (proaccelerin, labile factor) | F5 | 1 | −1.86 | −2.53 | −1.65 |
High mobility group box 2 | Hmgb2 | 1 | −3.83 | −3.59 | −3.40 |
S100 calcium binding protein A8 | S100a8 | 1 | −4.54 | −4.32 | −1.98 |
Phospholipase A2, Group VII | Pla2g7 | 1 | −2.43 | −3.27 | −3.20 |
Phospholipase A2 Group IVa | Pla2g4a | 1 | −1.88 | −2.06 | −1.83 |
Exercise regulates OA associated genes

Discussion
Contributions
Competing interests
Acknowledgments
Appendix A. Supplementary data
Supplementary Table S1. Primer sequences for qrtPCR.
Supplementary Table S2. KEGG pathways and Disease associated pathways regulated by exercise.
Supplementary Table S3. Temporal regulation of DEGS in healthy cartilage that are Associated with OA. The raw data has been deposited in a MIAME compliant database GEO (accession number GSE74898).
References
- Arthritis and Exercise.2006
- The effects of exercise on human articular cartilage.J Anat. 2006; 208: 491-512
- Osteoarthritis year in review 2014: rehabilitation and outcomes.Osteoarthritis Cartilage. 2014; 22: 1958-1988
- The Intensive Diet and Exercise for Arthritis Trial (IDEA): 18-month radiographic and MRI outcomes.Osteoarthritis Cartilage. 2015; 23: 1090-1098
- Positive effects of moderate exercise on glycosaminoglycan content in knee cartilage: a four-month, randomized, controlled trial in patients at risk of osteoarthritis.Arthritis Rheum. 2005; 52: 3507-3514
- Cyclic compressive mechanical stimulation induces sequential catabolic and anabolic gene changes in chondrocytes resulting in increased extracellular matrix accumulation.Matrix Biol. 2006; 25: 323-331
- Biomechanical signals inhibit IKK activity to attenuate NF-kappaB transcription activity in inflamed chondrocytes.Arthritis Rheum. 2007; 56: 3284-3296
- Regulation of chondrocytic gene expression by biomechanical signals.Crit Rev Eukaryot Gene Expr. 2008; 18: 139-150
- The basic science of articular cartilage: structure, composition, and function.Sports Health. 2009; 1: 461-468
- Position statement. Part one: immune function and exercise.Exerc Immunol Rev. 2011; 17: 6-63
- Position statement. Part two: maintaining immune health.Exerc Immunol Rev. 2011; 17: 64-103
- Basic components of connective tissues and extracellular matrix: elastin, fibrillin, fibulins, fibrinogen, fibronectin, laminin, tenascins and thrombospondins.Adv Exp Med Biol. 2014; 802: 31-47
- Sequential alterations in catabolic and anabolic gene expression parallel pathological changes during progression of monoiodoacetate-induced arthritis.PLoS One. 2011; 6: e24320
- Large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis.Arthritis Rheum. 2006; 54: 3533-3544
- Transcriptional profiling and pathway analysis of monosodium iodoacetate-induced experimental osteoarthritis in rats: relevance to human disease.Osteoarthritis Cartilage. 2007; 15: 1190-1198
- Regional dGEMRIC analysis in patients at risk of osteoarthritis provides additional information about activity related changes in cartilage structure.Acta Radiol. 2016; 57: 468-474
- Exercise and osteoarthritis.J Anat. 2009; 214: 197-207
- Markers of cartilage matrix metabolism in human joint fluid and serum: the effect of exercise.Osteoarthritis Cartilage. 1995; 3: 7-14
- Assessment of osteoarthritis candidate genes in a meta-analysis of nine genome-wide association studies.Arthritis Rheumatol. 2014; 66: 940-949
- Value of biomarkers in osteoarthritis: current status and perspectives.Ann Rheum Dis. 2013; 72: 1756-1763
- Osteoarthritis year 2013 in review: genetics and genomics.Osteoarthritis Cartilage. 2013; 21: 1443-1451
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.Nat Protoc. 2009; 4: 44-57
- Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.Nucleic Acids Res. 2009; 37: 1-13
- The KEGG databases at GenomeNet.Nucleic Acids Res. 2002; 30: 42-46
- Data, information, knowledge and principle: back to metabolism in KEGG.Nucleic Acids Res. 2014; 42: D199-D205
- Transcriptome-wide gene regulation by gentle treadmill walking during the progression of monoiodoacetate-induced arthritis.Arthritis Rheum. 2011; 63: 1613-1625
- Mechanotransduction at a distance: mechanically coupling the extracellular matrix with the nucleus.Nat Rev Mol Cell Biol. 2009; 10: 75-82
- Cartilage cell clusters.Arthritis Rheum. 2010; 62: 2206-2218
- The control of cell division in articular chondrocytes.Osteoarthritis Cartilage. 1993; 1: 137-146
- Effects of physical exercise on central nervous system functions: a review of brain region specific adaptations.J Mol Psychiatry. 2015; 3 (eCollection 2015): 3-13https://doi.org/10.1186/s40303-015-0010-8
- Association of COL1A2, COL2A1 and COL9A1 and primary osteoarthritis in a founder population.Clin Genet. 2005; 67: 359-360
- Chondrogenesis, chondrocyte differentiation, and articular cartilage metabolism in health and osteoarthritis.Ther Adv Musculoskelet Dis. 2012; 4: 269-285
- Joint immobilization prevents murine osteoarthritis and reveals the highly mechanosensitive nature of protease expression in vivo.Arthritis Rheum. 2012; 64: 2278-2288
- Fibroblast growth factor control of cartilage homeostasis.J Cell Biochem. 2013; 114: 735-742
- Fibroblast growth factor inhibits chondrocytic growth through induction of p21 and subsequent inactivation of cyclin E-Cdk2.J Biol Chem. 2001; 276: 29347-29352
- A network of transcriptional and signaling events is activated by FGF to induce chondrocyte growth arrest and differentiation.J Cell Biol. 2003; 161: 1053-1066
- Candidate gene association study of magnetic resonance imaging-based hip osteoarthritis (OA): evidence for COL9A2 gene as a common predisposing factor for hip OA and lumbar disc degeneration.J Rheumatol. 2011; 38: 747-752
- Basic fibroblast growth factor mediates transduction of mechanical signals when articular cartilage is loaded.Arthritis Rheum. 2004; 50: 526-533
- Subtractive gene expression profiling of articular cartilage and mesenchymal stem cells: serpins as cartilage-relevant differentiation markers.Osteoarthritis Cartilage. 2008; 16: 48-60
- Effect of physical therapy on pain and function in patients with hip osteoarthritis: a randomized clinical trial.JAMA. 2014; 311: 1987-1997
- Osteoarthritis year in review: outcome of rehabilitation.Osteoarthritis Cartilage. 2013; 21: 1414-1424
- Exercise as medicine – evidence for prescribing exercise as therapy in 26 different chronic diseases.Scand J Med Sci Sports. 2015; 25: 1-72
- Biomechanical signals suppress TAK1 activation to inhibit NF-kappaB transcriptional activation in fibrochondrocytes.J Immunol. 2007; 179: 6246-6254
- Biomechanical thresholds regulate inflammation through the NF-kappaB pathway: experiments and modeling.PLoS One. 2009; 4: e5262
- Biomechanical signals suppress proinflammatory responses in cartilage: early events in experimental antigen-induced arthritis.J Immunol. 2006; 177: 8757-8766
- Biomechanical strain regulates TNFR2 but not TNFR1 in TMJ cells.J Biomech. 2007; 40: 1541-1549
- Regulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus.J Biomech. 2006; 39: 1796-1803
- Effects of eccentric exercise on toll-like receptor 4 signaling pathway in peripheral blood mononuclear cells.J Appl Physiol (1985). 2012; 112: 2011-2018
- Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor.J Immunol. 2008; 181: 5082-5088
- Identification of a central role for complement in osteoarthritis.Nat Med. 2011; 17: 1674-1679
Article info
Publication history
Identification
Copyright
User license
Elsevier user license |
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy